1'-acetoxychavicol acetate has been researched along with Acquired Immunodeficiency Syndrome in 1 studies
*Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaneko, M; Kimura, T; Kobayashi, M; Murakami, N; Shiomi, A; Tamura, S; Ye, Y; Yoshida, M; Yoshikawa, M | 1 |
1 other study(ies) available for 1'-acetoxychavicol acetate and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
New Rev-export inhibitor from Alpinia galanga and structure-activity relationship.
Topics: Acquired Immunodeficiency Syndrome; Alpinia; Anti-HIV Agents; Benzyl Alcohols; Biological Assay; Biotinylation; Chemistry, Pharmaceutical; Drug Design; HeLa Cells; HIV-1; Humans; Plant Extracts; Plant Roots; rev Gene Products, Human Immunodeficiency Virus; Structure-Activity Relationship | 2009 |